Claudia Montlollor-Abalate

Evommune, Inc

Poster(s):

• W149 - EVO756: A Promising Oral MRGPRX2 Inhibitor Showing Strong Preclinical and Phase 1 Results
  Wednesday, June 25, 2025

  7:30am - 7:30pm East Coast USA Time